ConvaTec Group (LON:CTEC - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at Jefferies Financial Group in a research note issued to investors on Friday,London Stock Exchange reports. They currently have a GBX 325 price target on the stock. Jefferies Financial Group's target price would indicate a potential upside of 37.83% from the company's previous close.
CTEC has been the subject of several other reports. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a GBX 315 price objective on shares of ConvaTec Group in a research report on Wednesday. Stifel Nicolaus reissued a "buy" rating and set a GBX 315 price target on shares of ConvaTec Group in a research report on Wednesday, March 11th. Berenberg Bank raised their price target on shares of ConvaTec Group from GBX 330 to GBX 340 and gave the stock a "buy" rating in a research report on Thursday, January 22nd. Finally, Citigroup reissued an "outperform" rating and set a GBX 315 price target on shares of ConvaTec Group in a research report on Thursday, March 5th. Nine analysts have rated the stock with a Buy rating, According to MarketBeat.com, ConvaTec Group currently has an average rating of "Buy" and a consensus target price of GBX 319.67.
Check Out Our Latest Stock Report on CTEC
ConvaTec Group Stock Performance
Shares of ConvaTec Group stock opened at GBX 235.80 on Friday. The firm has a market capitalization of £4.61 billion, a P/E ratio of 27.42, a PEG ratio of 0.93 and a beta of 0.84. The company has a quick ratio of 0.96, a current ratio of 1.53 and a debt-to-equity ratio of 106.19. The company has a 50 day moving average price of GBX 230.44 and a 200 day moving average price of GBX 234.89. ConvaTec Group has a 52 week low of GBX 209.40 and a 52 week high of GBX 311.20.
Insider Buying and Selling at ConvaTec Group
In other news, insider Jonny Mason sold 291,149 shares of ConvaTec Group stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of GBX 234, for a total transaction of £681,288.66. 0.95% of the stock is currently owned by company insiders.
ConvaTec Group Company Profile
(
Get Free Report)
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ConvaTec Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ConvaTec Group wasn't on the list.
While ConvaTec Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.